AVDL · As filed with the SEC

Avadel Pharmaceuticals balance sheet, by quarter

The statement as Avadel Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

CONDENSED CONSOLIDATED BALANCE SHEETS · USD thousands

USD thousands	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024 Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023 Dec 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	79,813	63,402	56,370	51,371	28,582	28,847	35,794	31,167
Marketable securities	11,764	18,145	10,114	22,406	37,225	42,535	52,995	73,944
Accounts receivable, net	42,444	40,631	41,581	34,097	37,102	33,377	22,692	12,103
Inventories	23,905	23,484	20,406	20,298	16,097	13,313	11,928	10,380
Research and development tax credit receivable	—	—	—	—	—	927	1,293	1,322
Prepaid expenses and other current assets	14,300	13,443	10,787	6,036	8,252	6,781	11,333	5,286
Total current assets	172,226	159,105	139,258	134,208	127,258	125,780	136,035	134,202
Property and equipment, net	467	472	307	453	469	484	526	585
Operating lease right-of-use assets	2,544	2,721	2,896	1,702	1,930	2,154	2,374	2,591
Goodwill	16,836	16,836	16,836	16,836	16,836	16,836	16,836	16,836
Research and development tax credit receivable	—	—	—	—	—	252	360	332
Other non-current assets	7,375	8,023	8,652	11,037	11,760	12,015	11,768	10,152
Total assets	199,448	187,157	167,949	164,236	158,253	157,521	167,899	164,698
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt	—	—	—	—	—	—	—	0
Current portion of operating lease liability	740	723	706	582	725	866	953	934
Accounts payable	12,581	10,114	9,116	7,328	7,917	9,794	18,961	11,433
Accrued expenses	44,156	42,776	40,917	40,651	33,907	33,711	27,642	24,227
Other current liabilities	5,010	3,452	194	273	234	242	252	261
Total current liabilities	62,487	57,065	50,933	48,834	42,783	44,613	47,808	36,855
Long-term debt	—	—	—	—	—	—	—	0
Long-term operating lease liability	1,810	2,002	2,189	1,122	1,216	1,308	1,449	1,690
Royalty financing obligation	34,828	35,318	35,518	35,249	34,437	35,493	34,333	32,760
Other non-current liabilities	2,098	2,063	5,239	5,183	5,154	5,819	5,925	5,654
Total liabilities	101,223	96,448	93,879	90,388	83,590	87,233	89,515	76,959
Shareholders’ equity:
Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; zero issued and outstanding at September 30, 2025 and December 31, 2024	0	0	0	0	0	0	0	52
Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 97,235 issued and outstanding at September 30, 2025 and 96,518 issued and outstanding at December 31, 2024	972	967	966	965	963	961	960	898
Additional paid-in capital	910,391	902,970	896,663	891,791	886,787	880,202	874,018	855,452
Accumulated deficit	(789,562)	(789,582)	(799,247)	(794,328)	(789,285)	(786,660)	(772,838)	(745,496)
Accumulated other comprehensive loss	(23,576)	(23,646)	(24,312)	(24,580)	(23,802)	(24,215)	(23,756)	(23,167)
Total shareholders’ equity	98,225	90,709	74,070	73,848	74,663	70,288	78,384	87,739
Total liabilities and shareholders’ equity	199,448	187,157	167,949	164,236	158,253	157,521	167,899	164,698

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.